Healthcare DIVE November 21, 2019
President Donald Trump’s nominee for FDA commissioner pledged science, data and the law will be the guiding principles for decision making when faced with questions about FDA’s oversight of drugs and medical devices during testimony before the Senate HELP Committee on Wednesday.
MD Anderson radiation oncologist Stephen Hahn largely stuck to a familiar script on a gamut of issues including drug importation, FDA approval standards and encouraging competition and innovation.
Hahn told senators he would make it a priority to address drug shortages, examine anti-competitive processes used by brand drug manufacturers to protect biologics from biosimilar competition and protect the United States’ drug supply when considering drug importation.
Hahn expressed interest in boosting use of patient-focused endpoints in clinical trials...
Today's Sponsors
Today's Sponsor